癌症患者的败血症死亡率的演变:系统性审查和元分析
Luke Edwards1, Elizabeth Nelmes2, Maddalena Ardissino3
1Critical Care, Royal Marsden NHS Foundation Trust, London, UK.
Journal of the Intensive Care Society
|September 30, 2025
概括
患有败血症的重症监护室 (ICU) 的癌症患者的死亡率很高. 虽然随着时间的推移,死亡率正在下降,但需要进一步的研究来改善这些重症患者的治疗结果.
科学领域:
- 关键护理医学 关键护理医学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 败血症和败血性休克在接受重症监护单位 (ICU) 的癌症患者中越来越普遍.
- 这种脆弱人群的确切死亡率和败血症趋势尚不清楚.
- 这项研究解决了在ICU内的癌症患者中与败血症相关的死亡率的综合数据的需求.
研究的目的:
- 确定接受ICU治疗的癌症患者的败血症和败血性休克的综合死亡率 (ICU,医院,30天).
- 分析这些患者群体随着时间的推移死亡率的趋势.
- 为改善临床管理和结果提供证据.
主要方法:
- 使用MEDLINE和EMBASE数据库进行了系统的文献搜索.
- 使用元分析和多变量元回归来汇集死亡率数据并评估趋势.
- 包括的研究集中在ICU中患有败血症或败血性休克的成年癌症患者身上,结果使用已建立的质量工具进行评估.
主要成果:
- 集中ICU,医院和30天的败血症死亡率分别为44%,54%和49%.
- 综合ICU,医院和30天感染性休克死亡率分别为51%,62.6%和54%.
- 超回归显示了ICU和医院血病死亡率的下降趋势,以及感染性休克的ICU死亡率的下降.
结论:
- 在ICU中患有败血症的癌症患者的死亡率明显高于一般人群.
- 尽管随着时间的推移,死亡率的趋势正在下降,但风险仍然很大.
- 进一步的研究是必不可少的,以制定在这个患者队列中获得更好的结果的策略.
相关概念视频
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577
Comparing the Survival Analysis of Two or More Groups
561
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
561
Pneumonia III: Complications and Assessment
786
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
786


